Migalastat Approval Status
- FDA approved: No
- Generic name: migalastat
- Company: Amicus Therapeutics
- Treatment for: Fabry Disease
Migalastat (AT1001) is an investigational pharmacological chaperone in development for the treatment of Fabry disease.
Development Status and FDA Approval Process for migalastat
|Nov 28, 2016||Amicus Therapeutics Announces U.S. Regulatory Pathway for Migalastat for Fabry Disease|
|Sep 15, 2015||Amicus Therapeutics Plans to Submit NDA for Migalastat for Fabry Disease Following Positive Pre-NDA Meeting With FDA|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.